SG/PUT/VERTEX PHARMACEUTICALS/250/0.1/21.06.24 | Delayed Deutsche Boerse AG 12:43:20 2024-06-06 pm EDT | ||
| 0.001 EUR | 0.00% |
|
| 6 months | -99.74% | ||
| Current year | -99.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 0.001 | 0.00% |
| 24-06-05 | 0.001 | 0.00% |
| 24-06-04 | 0.001 | 0.00% |
| 24-06-03 | 0.001 | 0.00% |
| 24-05-31 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 06, 2024 at 12:43 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ6LG3 |
| ISIN | DE000SQ6LG30 |
| Date issued | 2022-12-20 |
| Strike | 250 $ |
| Maturity | 2024-06-21 (15 Days) |
| Parity | 10 : 1 |
| Emission price | 2.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.64 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.109 € |
| Spread % | 99.09% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
